Cipla sees weight-loss drugs as the biggest opportunity in the Indian market

Pharmacy Cipla LTD predicts that GLP-1 drugs used in the treatment of Type-2 diabetes and obesity have a definite new therapy in the Indian market and discovered a wider raid.

“The Indian market is particularly important to us, where we look at the entire GLP-1 category, not only Semaglidid,” Vohra in a media interaction on Friday after explaining the company’s June quarter results.

Semaglidid, a GLP-1 (Glucagon-like peptide-like peptide-like peptide-1) drug sold by Novo Nordisk under the Wegovy brand in India, comes out of a patent in March 2026.

“Our general thought will be quite definite in terms of a new therapy, a new part of the market and probably in terms of the greatest opportunity we have seen in the last five years,” Vohra said. “In this category, we are trying to develop a strategy about what to create for us in this category.”

The company also plans to launch Semaglutid in other markets from Patent, but Vohra refused to name certain markets. Jeepla will apply to the commercialization of the product with partners and on its own.

“In some markets that are important in the world, perhaps we will make two applications,” he said.

For Semagluid, Patent ends in 2026 in countries such as India, Canada and Brazil.

Cipla’s first quarter profit after the tax defeated the predictions, income was kidnapped. The company reported a pat La1.298 Crore with an increase of 10% annually La1,198.5 CRORE, Bloomberg 22 Intermediary Survey.

From La6,957 CRORE, Consolidated Revenue increased by 4% annually, but kidnapped Bloomberg predictions La7,057 Crore.

The company reported an EBITDA La1.778 Crore, EBITDA margin with an increase of 4% annually remained constant with 25.6% annually. FAVÖK means earnings before interest, tax, depreciation and depreciation.

“There were figures from an Indian business that was underlying this performance and generally growing at 6%, and in it, [trade] Generics and consumer health affairs, V Yuni Vohra added that branded prescription growth is lower because of a quiet season for acute treatments.

The company reported $ 226 million revenue from North American business for a quarter. The North American enterprise constitutes 28% of Jepla’s revenues.

“This is in the range we guided at the beginning of this quarter.

US uncertainty

While the uncertainty about the tariffs and regulatory changes in the United States continues, Vohra said Cipla’s work has already been significantly reduced.

“Fortunately or unfortunately, due to our facility problems in the last three years, due to the quotations on our sites, we started to risk our business. And we have built new facilities in the US,” he said.

While Vohra expects a little effect from the US policy changes, the company said that there would be no weakening effect that çocukların we are thinking about our business ”.

Cipla also faces price erosion on the blood cancer drug used to treat neuroendocrine tumors in the US this year. However, Vohra believes that the company has a product pipeline that will continue to increase growth in the next three to five years.

Cipla’s share price LaOn Friday, an increase of 1,535,00%at the National Stock Exchange, an increase of 3.17%.